Evolving concepts in HER2-low breast cancer: Genomic insights, definitions, and treatment paradigms...Impact Journals LLC
The first patient has been dosed in the global multicenter Phase I Trial of ISM6331, a novel pan-TEAD inhibitor develope...InSilico Medicine
University of Barcelona team describes a mechanism for eliminating harmful cells from cancer treatment...University of Barcelona
University of Barcelona team describes a mechanism for eliminating harmful cells from cancer treatment...University of Barcelona
University of Barcelona team describes a mechanism for eliminating harmful cells from cancer treatment...University of Barcelona